The DOI matches its Crossref record.
Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (cgp 69846a) after intravenous and subcutaneous administration
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antisense oligonucleotides do not readily cross the BBB.73”
From RAB10: an Alzheimer’s disease resilience locus and potential drug target (2018) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 24
- Helene, 1990, Specific regulation of gene expression by antisense, sense and antigene nucleic acids, Biochim Biophys Acta, 1049, 99, 10.1016/0167-4781(90)90031-V · DOI · Paper page
- Monia, 1996, Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase, Nat Med, 2, 668, 10.1038/nm0696-668 · DOI · Paper page
- Dean, 1996, Inhibition of human tumor cell lines in nude mice by an antisense inhibitor of PKC-α expression, Cancer Res, 56, 3499
- Agrawal, 1992, Antisense oligonucleotides as antiviral agents, Trends Biotechnol Sci, 10, 152, 10.1016/0167-7799(92)90203-8 · doi:10.1016/0167-7799(92)90203-8
- Goodarzi, 1992, Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice, Biopharmacol Drug Dispos, 13, 221, 10.1002/bdd.2510130308 · doi:10.1002/bdd.2510130308
- Iversen, 1991, In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue, AntiCancer Drug Design, 6, 531
- Cossum, 1993, Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats, J Pharmacol Exp Ther, 267, 1181
- Sands, 1994, Biodistribution and metabolism of internally 3H-labeled oligonucleotides. 1. Comparison of a phosphodiester and a phosphorothioate, Mol Pharmacol, 45, 932
- Agrawal, 1995, Pharmacokinetics of antisense oligonucleotides, Clin Pharmacokinet, 28, 7, 10.2165/00003088-199528010-00002 · DOI · Paper page
- Zhang, 1995, Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM-91) developed as a therapeutic agent for human immunodeficiency virus type-1, Biochem Pharmacol, 49, 929, 10.1016/0006-2952(95)00010-W · DOI
- Crooke, 1996, Pharmacokinetic properties of several oligonucleotide analogs in mice, J Pharmacol Exp Ther, 277, 923
- Rifai, 1996, Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides iin mice, Am J Pathol, 149, 717
- Cossum, 1994, Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats, J Pharmacol Exp Ther, 269, 89
- Saijo, 1994, Pharmacokinetics, tissue distribution and stability of antisense oligodeoxynucleotide phosophorothioate ISIS 3466 in mice, Oncol Res, 6, 243
- Leeds, 1996, Quantification of phosphorothioate oligonucleotides in human plasma, Anal Biochem, 235, 36, 10.1006/abio.1996.0088 · DOI
- Graham, 1993, Tritium labeling of antisense oligonucleotides by exchange with tritiated water, Nucleic Acids Res, 21, 3737, 10.1093/nar/21.16.3737 · DOI
- Crooke, 1991, In vitro toxicology and pharmacokinetics of antisense oligonucleotides, Anticancer Drug Design, 6, 609
- Beck, 1996, Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial cells, Pharmacol Res, 13, 1028, 10.1023/A:1016002606705 · DOI
- Spitzer, 1988, Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides, Nucleic Acids Res, 16, 11691, 10.1093/nar/16.24.11691 · DOI
- Temsamani, 1993, Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice, Antisense Res Dev, 3, 277, 10.1089/ard.1993.3.277 · DOI
- Tang, 1993, Self-stabilized anti-sense oligodeoxynucleotide phosphorothioates: Properties and anti-HIV activity, Nucleic Acids Res, 21, 2729, 10.1093/nar/21.11.2729 · DOI
- Zhang, 1995, In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats, Clin Chem, 41, 836, 10.1093/clinchem/41.6.836 · DOI
- Galbraith, 1994, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey, Antisense Res Dev, 4, 201, 10.1089/ard.1994.4.201 · DOI · Paper page
- Cornish, 1993, Cardiovascular effects of a phosphorothioate oligonucleotide with a sequence antisense to p53 in the conscious rhesus monkey, Pharmacol Commun, 3, 239
Cited by
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
Discovery and Development of Therapeutic Aptamers
Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105547 · Cited by 320
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Self-citation
Metadata
- Authors
- Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., & Nicklin, P. L.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 54
- Issue
- 6
- Pages
- 657-668
- ISSN
- 0006-2952
- Cited by
- 103
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (cgp 69846a) after intravenous and subcutaneous administration. https://app.cochat.ai/papers/10.1016/s0006-2952(97)00190-1
- The paper
- Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., & Nicklin, P. L. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (cgp 69846a) after intravenous and subcutaneous administration. Biochemical Pharmacology. https://doi.org/10.1016/s0006-2952(97)00190-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.